REG - Oxford Instruments - Trading Update

Oxford InstrumentsAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nRSN2721Aa&default-theme=true

RNS Number : 2721A  Oxford Instruments PLC  14 April 2026

 

Oxford Instruments plc

Full-year trading update - 14 April 2026

 

Strong second half - full year in line with expectations
Continued strong order momentum in Advanced Technologies

Oxford Instruments plc ("Oxford Instruments" or "the Group"), a leading
provider of scientific technology tools, software and expertise to academic
and commercial partners, is today issuing a trading update for the year ended
31 March 2026 for continuing operations1.

We expect to deliver a resilient full-year performance in line with market
expectations2. Full-year order intake for the Group is expected to be up c. 8%
on an organic constant currency (OCC)3 basis versus prior year, with a
book-to-bill ratio of c. 1.07.

After a tariff-disrupted start to the financial year, we have seen continued
positive quarter-on-quarter order intake momentum in our Imaging &
Analysis ("I&A") division. Following a return to growth in H2, full-year
order intake is expected to be in line with the prior year on a reported
basis, and marginally up versus prior year on an OCC basis.

Within our Advanced Technologies ("AT") division, tailwinds in the compound
semiconductor market, and increasing traction with volume manufacturing
customers, have driven c. 30% OCC year-on-year order growth. Order intake
accelerated in H2, mainly driven by large US and European commercial
customers. Following receipt of a significant multi-year order in April 2026,
the current AT order book materially covers planned revenue for FY27, with
orders now extending into FY28.

As anticipated, strong execution and improving market conditions in the second
half delivered a Group revenue performance significantly ahead of H1, with H2
revenue marginally below the prior year on a reported basis, moving to
slightly positive growth on an OCC basis.

Group operating profit margin continued to benefit from the cost restructuring
actions undertaken at our Belfast-based imaging business, and from the
expected margin improvement from H2 revenue growth.

The first £50m tranche of the share buyback programme was completed at the
end of February. As at 31 March 2026, £11.7m of the second £50m tranche had
been completed.

Richard Tyson, Chief Executive Officer, commented:

"The Group's strong execution in the second half, coupled with excellent order
growth in Advanced Technologies, led to a resilient full-year performance
against a challenging external backdrop; testament to the great work and
agility of all of the team at Oxford Instruments.  With good momentum and a
strong order book we are well positioned for growth into the new financial
year and beyond."

 

FY26 preliminary results

Oxford Instruments management will present its full-year results to analysts
and investors at Deutsche Numis, 21 Moorfields, London, EC2Y 9DB on 9 June
2026.

Notes:

1.      Excludes the NanoScience business and directly related costs
which exited the Group upon final deal closing. All numbers unaudited and
based on current expectations.

2.      The mean of consensus estimates for reported full year FY26
results are for revenue of £420.7m, adjusted operating profit of £71.3m, and
adjusted operating margin of 16.9%. Please refer to the Company website for
more details of how consensus is calculated. Adjusted items exclude the
amortisation and impairment of acquired intangible assets, acquisition items,
business reorganisation costs, other significant non-recurring items, and the
mark-to-market movement of financial derivatives

3.      Constant currency numbers are prepared on a month-by-month basis
using the translational and transactional exchange rates which prevailed in
the previous year rather than the actual exchange rates which prevailed in the
year. Transactional exchange rates include the effect of our hedging
programme.

 

The financial information in this trading update is unaudited. LEI:
213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Director of Investor Relations
               07776 433916

Stephen.lamacraft@oxinst.com (mailto:Stephen.lamacraft@oxinst.com)

 

 

MHP Group

Katie Hunt/Tim
Rowntree/
07884 494112

Hugo Harris
 
oxfordinstruments@mhpgroup.com (mailto:oxfordinstruments@mhpgroup.com)

 

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide
with

market-leading scientific technology and expertise across its key market
segments: materials analysis, semiconductors, and healthcare & life
science. Innovation is the driving force behind Oxford Instruments' growth and
success, supporting its core purpose to accelerate the breakthroughs that
create a brighter future for our world. The vigorous search for new ways to
make our world greener, healthier and more productive is driving unprecedented
levels of R&D investment in new materials and techniques to support
productivity and decarbonisation worldwide, creating a significant opportunity
for Oxford Instruments to grow. Oxford Instruments holds a unique position to
anticipate global drivers and connect academic researchers with commercial
applications engineers, acting as a catalyst that powers real world progress.
Founded in 1959 as the first technology business to be spun out from Oxford
University, Oxford Instruments is now a global, FTSE250 company listed on the
London Stock Exchange (OXIG). For more information, visit www.oxinst.com
(https://protect.checkpoint.com/v2/r06/___http:/www.oxinst.com/___.ZXV3MjpuZXh0MTU6YzpvOjU3OGJhOTBlYjg2NGJjZDk0N2JiNjg1ZmViNmUxNWE0Ojc6MDA2NDozNzBjNmVhYzI4YmI2MDE0MmM5Y2UyNmU1NTU4N2M0Y2MxMzhiOGM2NzBiMzFkN2UxMTUzN2NlZjc0MTJmNmUyOnA6VDpU)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTAKNBNABKDFQD



            Copyright 2019 Regulatory News Service, all rights reserved